



# MMV - Malaria Drugs Discover, Develop, and Deliver



# Medicines for Malaria Venture



Gro Harlem Brundtland

Sir Richard Sykes

**MMV - A Partnership between Public and Private sectors**

**Launch Nov 3rd, 1999**



Medicines for Malaria Venture


Value added through effective Public-Private Partnership ....



### MMV Inputs

- \$\$\$
- Drug Profile
- Partner Management
- Link to WHO/GMP/Policy
- Malaria Expertise
- Evaluation / Monitoring

**Public**



### MMV Gets

- Rights in DEC
- IPR in 'Field'
- Drug Supply
- Return on non DEC Sales

### Industry Inputs

- Chemistry IPR
- Toxicology
- Know How
- Assets in Kind
- Technology
- Liability Insurance

For the 'Public Good'

**Private**

### Industry Gets

- Rights in non DEC
- IPR outside 'Field'
- Validation of Technology
- PR Benefit **Corporate Citizenship and Responsibility**
- HR Benefit **Staff Satisfaction**

**Public+Private = leveraged cost**

# MMV Product Profiles



## For Uncomplicated Malaria

- Efficacy against drug resistant strains
- Cure within three days
- Low propensity to generate rapid resistance
- Safe in small children (< 6 mos.)
- Safe in pregnancy
- Appropriate formulations and packaging
- Low cost of goods <\$1.00 for an adult Rx



# MMV Product Profiles




## Further indications of interest

- Intermittent preventive treatment in pregnancy
- Intermittent preventive treatment in early infancy
- Treatments suitable for emergency situations e.g. single dose treatment for refugee camps
- *P. vivax* malaria (including radical cure)
- Severe malaria
- Prophylaxis



# MMV Portfolio 1<sup>st</sup> Q 2007

## Manage to Budget





**Renia Coghlan**  
**Associate Director, Global Access**  
**[coghlanr@mmv.org](mailto:coghlanr@mmv.org)**